This Clinical Study is to Test Efficacy and Safety of BT595 in Chronic Primary Immune Thrombocytopenia (ITP)

PHASE3CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Immune Thrombocytopenia
Interventions
BIOLOGICAL

BT595

Trial Locations (22)

1083

Investigational site # 3601, Budapest

1431

Investigational site # 3598, Sofia

1756

Investigational site # 3591, Sofia

3529

Investigational site # 3602, Miskolc

4000

Investigational site # 3593, Plovdiv

4032

Investigational site # 3604, Debrecen

4400

Investigational site # 3603, Nyíregyháza

5800

Investigational site # 3597, Pleven

7621

Investigational site # 3606, Pécs

9010

Investigational site # 3596, Varna

9023

Investigational site # 3607, Győr

10034

Investigational site # 4202, Prague

11000

Investigational site # 3811, Belgrade

11080

Investigational site # 3813, Belgrade

13353

Investigational site # 4901, Berlin

18000

Investigational site #3814, Niš

21000

Investigational site # 3812, Novi Sad

28006

Investigational site # 3403, Madrid

28007

Investigational site # 3404, Madrid

81377

Investigational Site #4902, München

Unknown

Investigational site #3401, Málaga

07012

Investigational site # 3402, Palma de Mallorca

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Syneos Health

OTHER

lead

Biotest

INDUSTRY